5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Labcorp Holdings Inc (LH) stock reached a 52-week high of 289.61 USD, marking a significant milestone for the $24 billion healthcare diagnostics giant. According to InvestingPro analysis, the stock appears slightly overvalued at current levels. Over the past year, the stock has experienced a substantial increase, with a 1-year change of 34.95%, supported by solid revenue growth of 7.98%. This upward trend reflects investor confidence and the company’s strong performance in the healthcare sector, though the stock now trades at a relatively high P/E ratio of 31.86. The 52-week high comes as Labcorp continues to expand its services and innovations in medical testing, positioning itself as a key player in the industry. InvestingPro data reveals management has been aggressively buying back shares, with 8 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Labcorp Holdings Inc. has declared a quarterly cash dividend of $0.72 per share, payable on December 11, 2025, to shareholders of record as of November 26, 2025. The company also completed the acquisition of select oncology assets from BioReference Health for $192.5 million, with the potential for an additional $32.5 million based on performance. Additionally, Labcorp has collaborated with Roche to implement FDA-cleared digital pathology scanners to address a projected shortage of pathologists in the U.S. by 2030. In a significant development, Labcorp launched the first FDA-cleared blood test for Alzheimer’s disease, offering a less invasive diagnostic option. On the financial front, Jefferies has raised its price target for Labcorp to $300, maintaining a Buy rating following a 1% top-line beat in the company’s quarterly results. This performance was driven by a 6% increase in the Base Business segment, with an improved book-to-bill ratio of 1.18. These developments reflect Labcorp’s ongoing efforts to expand its services and improve its financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.